MedTrace Logo

Hereditary Hemorrhagic Telangiectasia and Neurovascular Manifestations, in the Danish HHT Database

NCT05933330 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2025-03-30

No results posted yet for this study

Summary

With a described prevalence of brain arteriovenous malformations (CAVM) of 12.8% in HHT patients, of whom 10% presents with intracranial hemorrhage, HHT pose a risk of devastating intracranial hemorrhage.

The main objective of the study is to challenge current statements (pros and cons) regarding systematic screening of asymptomatic HHT patients for neurovascular manifestations.

The investigators are thus seeking to answer a question many screening programs have faced.

A screening program should screen for a manageable problem, by a method that is considered cost effective and does not cause negative effect, even when extrapolated to a large cohort. Finally, the positive effect of screening program should outweigh the negative and not cause unnecessary concerns for the patients. The investigators are seeking to draw perspectives from the results to general questions about screening programs.

Conditions

  • Telangiectasia, Hereditary Hemorrhagic
  • Intracranial Arteriovenous Malformations

Interventions

OTHER

Brain MRI

All included patients receive an MRI of the brain

Sponsors & Collaborators

  • Odense University Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-01
Primary Completion
2025-03-31
Completion
2025-07-31

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05933330 on ClinicalTrials.gov